机构:[1]Department of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.昆明医科大学附属第一医院医技科室病理科[2]Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.[3]School of Basic Medicine, Central South University, Changsha 410031, Hunan, China.[4]National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.[5]Key Laboratory of Hunan Province in Neurodegenerative Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China.
Mammalian STE20-like kinase 1 (MST1/STK4/KRS2) is a highly conserved serine/threonine kinase and a central member of the Hippo signaling pathway. STK4 has been reported to play important roles in various tumors, but a systematic and comprehensive study of its function in clear cell renal cell carcinoma (ccRCC) has not been conducted.In this study, we used immunohistochemistry (IHC), western blot (WB), quantitative real-time PCR (qPCR) experiments, and bioinformatics analysis to comprehensively analyze the expression, prognostic value, and immune infiltration of STK4 in ccRCC.Analysis of the TCGA database showed that the expression level of the STK4 gene in ccRCC patients depended on tumor stage, grade, and distant lymphatic metastasis. This was further confirmed by the results of IHC, WB, and qPCR. In addition, we used the receiver operating characteristic curve (ROC curve) to elucidate the diagnostic value of STK4 in ccRCC patients. According to the findings of the TIMER database, the high expression of STK4 is significantly associated with the survival of kidney cancer (including ccRCC) patients (p < 0.001), suggesting that STK4 is a reliable prognostic predictor. We then used gene set enrichment analysis (GSEA) to explore the mechanisms behind STK4 function in ccRCC. We found that STK4 may play a role in immune regulation interactions. Subsequently, we performed immune infiltration analysis of STK4. The results showed that STK4 may regulate the development of ccRCC by affecting the immune infiltration of NK and pDC cells.STK4 may be a prognostic marker for ccRCC and may help identify new strategies for treating ccRCC patients.
基金:
This work was supported by Hunan Provincial Innovation Foundation for Postgraduate (No. CX20230328).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2024]版:
无
最新[2023]版:
大类|3 区医学
小类|3 区细胞生物学3 区老年医学
第一作者:
第一作者机构:[1]Department of Pathology, First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Bai Zi-Yuan,Peng Lu-Shan,Li Run-Qi,et al.STK4 is a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma[J].Aging.2023,15:doi:10.18632/aging.205127.
APA:
Bai Zi-Yuan,Peng Lu-Shan,Li Run-Qi,Peng Xianchu&Yang Zhe.(2023).STK4 is a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma.Aging,15,
MLA:
Bai Zi-Yuan,et al."STK4 is a prognostic biomarker correlated with immune infiltrates in clear cell renal cell carcinoma".Aging 15.(2023)